Relation Therapeutics, a computational drug discovery startup focused on osteoporosis, has secured an additional $35 million in funding, bringing their total seed financing to $60 million. The backing comes from a group of investors including Nvidia’s NVentures, DCVC, Deerfield Management Company, Khosla Ventures, Jonathan Milner of Abcam, ARK Invest, and Magnetic Ventures.
The venture arm of Nvidia, a prominent player in the world of supercomputing, sees potential in Relation Therapeutics’ innovative approach to tackling osteoporosis, a field that has seen limited advancements in recent years. With this new funding, Relation Therapeutics is gearing up to advance their research towards clinical trials.
Osteoporosis, a condition characterized by weak and brittle bones, affects a significant portion of the population, particularly older individuals and postmenopausal women. By leveraging cutting-edge technology and computational analysis, Relation Therapeutics aims to develop new and more effective treatments for this widespread health issue.
The support from investors like Nvidia and others underscores the potential impact of Relation Therapeutics’ work in the field of osteoporosis research. With this latest round of funding, the company is well-positioned to further their mission of advancing drug discovery and bringing much-needed innovation to the treatment of osteoporosis.
